Jason Park, Ph.D, CEO & Co-Founder of Empress Therapeutics and Operating Partner, Flagship Pioneering, examines why technologies such as artificial intelligence (AI) and machine learning (ML) will prove essential for the discovery of new small molecule medicines.   For the better part of the last century, drug discovery was focused on chemical compounds and was […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!